Research analysts covering Cardiol Therapeutics.
Recent press releases and 8-K filings for CRDL.
Cardiol Therapeutics Inc. Announces Private Placement Offering
CRDL
- Cardiol Therapeutics Inc. entered into an underwriting agreement with Canaccord Genuity Corp. on January 23, 2026, for a private placement offering.
- The company proposes to sell 11,423,078 units at a price of $1.30 per unit, aiming for aggregate gross proceeds of $14,850,001.40.
- Each Offered Unit consists of one Common Share and one-half Common Share purchase warrant.
- Each warrant will entitle the holder to acquire an additional Common Share at an exercise price of $1.75.
4 days ago
Cardiol Therapeutics Announces $13.5 Million Bought Deal Financing
CRDL
New Projects/Investments
- Cardiol Therapeutics Inc. announced a "bought deal" private placement offering on January 16, 2026, for gross proceeds of $13.5 million.
- The offering involves the sale of 10,384,616 units at a price of $1.30 per unit, with each unit consisting of one Class A common share and one-half of one common share purchase warrant.
- The Underwriter, Canaccord Genuity Corp., has an option to purchase up to an additional 1,038,462 units for up to $1,350,000 in additional gross proceeds.
- The company intends to use the net proceeds to advance its research and clinical development programs and for general and administrative expenses, working capital, and other expenses.
- The offering is scheduled to close on or about January 23, 2026.
Jan 26, 2026, 6:12 PM
Cardiol Therapeutics Announces Closing of Bought Deal Financing
CRDL
New Projects/Investments
- On January 23, 2026, Cardiol Therapeutics Inc. closed its previously announced private placement of units, including the full exercise of the over-allotment option.
- The offering generated gross proceeds of $14.85 million from the issuance of 11,423,078 Units at a price of $1.30 per Unit.
- Each Unit consists of one Class A common share and one-half of one Common Share purchase warrant, with each whole warrant exercisable at $1.75 per share for a period of 24 months.
- The net proceeds from the financing are intended to advance the company's research and clinical development programs, as well as cover general and administrative expenses and working capital.
Jan 23, 2026, 2:26 PM
Cardiol Therapeutics Announces Bought Deal Financing
CRDL
New Projects/Investments
- Cardiol Therapeutics Inc. (CRDL) announced a bought deal financing for gross proceeds of $13.5 million.
- The offering consists of 10,384,616 units at an offering price of $1.30 per unit.
- Each unit includes one Class A common share and one-half of one Common Share purchase warrant, with warrants exercisable at $1.75 per share for 24 months.
- The company plans to use the net proceeds to advance its research and clinical development programs and for general and administrative expenses, working capital, and other expenses.
- The closing of the offering is scheduled for on or about January 23, 2026.
Jan 16, 2026, 1:57 PM
Cardiol Therapeutics achieves 50% patient enrollment in Phase III MAVERIC trial
CRDL
New Projects/Investments
- Cardiol Therapeutics Inc. has achieved 50% patient enrollment in its pivotal Phase III MAVERIC trial, which is evaluating CardiolRx™ for the prevention of disease recurrence in patients with recurrent pericarditis.
- The company anticipates full enrollment in Q2 2026.
- This milestone is a key execution and risk-reduction inflection point for Cardiol's lead registrational program.
- The trial is actively enrolling patients across more than 15 leading cardiovascular centers in the U.S., with additional sites being activated in Europe and Canada.
Jan 13, 2026, 12:30 PM
Cardiol Therapeutics Announces Positive Phase 2 ARCHER Trial Results for Acute Myocarditis
CRDL
New Projects/Investments
Product Launch
- Cardiol Therapeutics announced positive results from its phase 2 ARCHER trial for Cardiol Rx in acute myocarditis, reporting a significant reduction of 9.2 grams in left ventricular mass compared to placebo over 12 weeks. This reduction, indicative of structural cardiac improvement and resolution of inflammation, was observed despite the trial not reaching statistical significance for its two primary endpoints.
- The Cardiol Rx therapy was well tolerated, with adverse event rates comparable to placebo.
- These findings serve as a second proof of concept for Cardiol Therapeutics' therapies, reinforcing confidence in the ongoing pivotal phase 3 MAVERICK trial for recurrent pericarditis and supporting the accelerated development of the next-generation CRD38 program for broader inflammatory heart conditions, including heart failure.
- The company projects the recurrent pericarditis market to reach $600 million to $1 billion in annual sales by 2027-2028, with the heart failure market representing a significantly larger opportunity.
Dec 1, 2025, 1:30 PM
Cardiol Therapeutics Announces Positive ARCHER Trial Results for Acute Myocarditis
CRDL
New Projects/Investments
- Cardiol Therapeutics announced positive results from its global phase II ARCHER trial for Cardiol Rx in acute myocarditis, demonstrating a significant reduction in left ventricular mass (over 9 grams) compared to placebo.
- The ARCHER trial, which enrolled 109 patients across 34 research centers, showed Cardiol Rx was well tolerated with adverse event rates comparable to placebo, and indicated meaningful structural cardiac improvement.
- These findings provide clinical proof of concept for Cardiol Rx, strengthening confidence in the ongoing pivotal phase III MAVERICK trial for recurrent pericarditis.
- The results also support the accelerated development of the next-generation subcutaneous drug candidate, CRD38, for conditions like heart failure, with the company aiming to accelerate IND-enabling work and pursue partnerships for its development in this broader market.
Dec 1, 2025, 1:30 PM
Cardiol Therapeutics Announces Positive Phase 2 ARCHER Trial Results
CRDL
New Projects/Investments
Product Launch
- Cardiol Therapeutics announced positive results from its Phase 2 ARCHER trial for Cardiol Rx in acute myocarditis, demonstrating a significant reduction in left ventricular (LV) mass of just over 9 grams compared to placebo.
- The ARCHER trial, which enrolled 109 patients across 34 research centers, showed that Cardiol Rx was well tolerated with adverse event rates comparable to placebo.
- Although the trial did not reach statistical significance for its two primary endpoints, it provided compelling biological evidence of meaningful structural recovery in the hearts of patients with acute myocarditis.
- These findings reinforce confidence in the ongoing pivotal Phase 3 MAVERICK trial for recurrent pericarditis and provide a translational link to the CRD38 next-generation subcutaneous formulation for inflammatory heart disease, including heart failure.
- Cardiol Therapeutics plans to accelerate IND-enabling work for CRD38 and explore partnerships for its development in broader heart failure markets.
Dec 1, 2025, 1:30 PM
Cardiol Therapeutics Announces Positive Phase II ARCHER Trial Results for CardiolRx™
CRDL
New Projects/Investments
- Cardiol Therapeutics Inc. announced positive new data from its Phase II ARCHER trial for CardiolRx™ in patients with acute myocarditis on December 1, 2025.
- The trial demonstrated a significant 9.2-gram reduction in left ventricular (LV) mass (p=0.0117) and improvements in other cardiac MRI measures, indicating structural heart recovery.
- These findings provide clinical evidence that CardiolRx™ reduces inflammation-driven structural damage in the heart and strengthen the rationale for the ongoing Phase III MAVERIC trial in recurrent pericarditis and broader development in inflammatory cardiac conditions.
- CardiolRx™ was also found to be safe and well tolerated.
Dec 1, 2025, 1:05 PM
Cardiol Therapeutics Inc. Reports Decreased Net Loss, Extended Cash Runway, and Clinical Trial Progress
CRDL
Earnings
Guidance Update
New Projects/Investments
- Cardiol Therapeutics Inc. reported a net loss of $(9,964,281) for the three months ended September 30, 2025, and $(26,606,305) for the nine months ended September 30, 2025, representing a decrease in net loss compared to the prior year, primarily due to lower general and administration expenses despite increased research and development costs.
- The company's cash and cash equivalents were $11,622,408 as of September 30, 2025 , which increased to $25,803,549 as of November 7, 2025, after completing a US$11.4 million financing. This capital is expected to fund operations into Q3 2027.
- Cardiol Therapeutics announced topline results from the ARCHER trial in August 2025, indicating notable improvement in ECV for CardiolRx™ , and continues its pivotal Phase III MAVERIC trial for recurrent pericarditis, for which CardiolRx™ holds FDA Orphan Drug Designation.
Nov 13, 2025, 9:24 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more